Document is current
Any future updates will be listed below
-
Authors
Tsimberidou, Apostolia-Maria https://orcid.org/0000-0003-2713-233X
Van Morris, Karlyle
Vo, Henry Hiep
Eck, Stephen
Lin, Yu-Feng
Rivas, Jorge Mauricio
Andersson, Borje S.
-
Funding
Funding for this research was provided by:
Supported in part by donor funds from Jamie’s Hope, Mr. and Mrs. Zane W. Arrott, and Mr. and Mrs. Steven McKenzie for Dr. Tsimberidou’s Personalized Medicine Program
National Institutes of Health/National Cancer Institute (P30 CA016672 (The University of Texas MD Anderson Cancer Center))
- License Information
-
More Information
Article History
Received: 10 March 2021
Accepted: 18 June 2021
First Online: 30 June 2021
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Research Funding (Institution): Immatics, Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, and Tvardi Therapeutics. Consulting or Advisory Role: Covance, Genentech, and Tempus. Dr. Van Karlyle Morris has the following financial relationships to disclose: Research Funding: Boehringer Ingelheim and Immatics. Research Funding (Institution): Bristol-Myers Squibb, Array Biopharma, and EMD Serono. Honoraria: Products in Knowledge. Consulting or Advisory Role: Array Biopharma, Incyte, SERVIER, Boehringer Ingelheim. Dr. Stephen Eck has the following financial relationships to disclose: Board director: Luminex and Circulogene. Stock ownership: Immatics Dr. Yu-Feng Lin has the following financial relationships to disclose: Stock ownership: Immatics Dr. Jorge M Rivas has the following financial relationships to disclose: Stock ownership: Immatics Dr. Henry Hiep Vo and Dr. Borje S Andersson report no relevant conflicts of interest.
